Alexion Pharmaceuticals (NASDAQ:ALXN)‘s stock had its “outperform” rating reiterated by equities research analysts at Credit Suisse Group in a research note issued on Thursday. They currently have a $147.00 price objective on the biopharmaceutical company’s stock. Credit Suisse Group’s target price would suggest a potential upside of 20.37% from the company’s previous close.

Several other analysts have also recently weighed in on the company. Raymond James Financial reissued an “outperform” rating and set a $130.00 price objective (down from $178.00) on shares of Alexion Pharmaceuticals in a report on Thursday, January 4th. They noted that the move was a valuation call. UBS Group cut Alexion Pharmaceuticals from a “strong-buy” rating to an “outperform” rating in a report on Thursday, January 4th. BidaskClub raised Alexion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Wednesday, December 27th. Robert W. Baird raised Alexion Pharmaceuticals from a “neutral” rating to an “outperform” rating and set a $150.00 price objective for the company in a report on Monday, December 18th. Finally, Leerink Swann reaffirmed a “buy” rating and issued a $169.00 price target on shares of Alexion Pharmaceuticals in a research note on Wednesday, December 6th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and nineteen have issued a buy rating to the company’s stock. Alexion Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $153.10.

Alexion Pharmaceuticals (NASDAQ:ALXN) traded down $2.36 during trading on Thursday, hitting $122.12. The company had a trading volume of 2,074,900 shares, compared to its average volume of 2,310,764. The company has a market capitalization of $27,280.00, a PE ratio of 54.52, a price-to-earnings-growth ratio of 1.04 and a beta of 1.17. Alexion Pharmaceuticals has a fifty-two week low of $96.18 and a fifty-two week high of $149.34. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.96 and a quick ratio of 2.51.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.44 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.32 by $0.12. The firm had revenue of $859.00 million during the quarter, compared to analysts’ expectations of $864.34 million. Alexion Pharmaceuticals had a return on equity of 12.55% and a net margin of 14.57%. The company’s quarterly revenue was up 7.5% compared to the same quarter last year. During the same period in the previous year, the business posted $1.23 EPS. equities analysts predict that Alexion Pharmaceuticals will post 4.82 EPS for the current fiscal year.

In other Alexion Pharmaceuticals news, CEO Ludwig Hantson sold 2,553 shares of the company’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $121.63, for a total transaction of $310,521.39. Following the completion of the transaction, the chief executive officer now owns 36,172 shares of the company’s stock, valued at approximately $4,399,600.36. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 4.35% of the company’s stock.

Large investors have recently added to or reduced their stakes in the business. Valeo Financial Advisors LLC acquired a new position in Alexion Pharmaceuticals during the 3rd quarter worth approximately $147,000. Dupont Capital Management Corp acquired a new position in Alexion Pharmaceuticals during the 3rd quarter worth approximately $156,000. BT Investment Management Ltd acquired a new position in Alexion Pharmaceuticals during the 3rd quarter worth approximately $165,000. YorkBridge Wealth Partners LLC raised its stake in shares of Alexion Pharmaceuticals by 221.7% during the 2nd quarter. YorkBridge Wealth Partners LLC now owns 1,425 shares of the biopharmaceutical company’s stock worth $173,000 after purchasing an additional 982 shares in the last quarter. Finally, Beacon Investment Advisory Services Inc. bought a new stake in shares of Alexion Pharmaceuticals during the 3rd quarter worth approximately $201,000. 94.27% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: This piece of content was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another website, it was stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/01/18/credit-suisse-group-reaffirms-buy-rating-for-alexion-pharmaceuticals-alxn.html.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.